Demographics of Brain Metastasis

Johnson, John D.; Young, Byron

doi:10.1016/s1042-3680(18)30365-6

Cited by 300 publications

(173 citation statements)

References 69 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…In addition, detection of metastatic lesions has improved because of increased use of magnetic resonance imaging. Patients with BM often have poor prognosis and survival [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases

et al. 2016

View full text Add to dashboard Cite

Brain metastases are the most common intracranial malignancy. Many approaches, including radiation therapy, surgery, and cytotoxic chemotherapy, have been used to treat patients with brain metastases depending on the patient's disease burden and symptoms. However, stereotactic surgery (SRS) has revolutionized local treatment of brain metastases. Likewise, targeted therapies, including small-molecule inhibitors and monoclonal antibodies that target cancer cell metabolism or angiogenesis, have transformed managing systemic disease. Prospective data on combining these treatments for synergistic effect are limited, but early data show favorable safety and efficacy profiles.The combination of SRS and targeted therapy will further individualize treatment, potentially obviating the need for cytotoxic chemotherapy or whole-brain radiation.There is a great need to pursue research into these exciting modalities and novel combinations to further improve the treatment of patients with brain metastases.This article discusses reported and ongoing clinical trials assessing the safety and efficacy of targeted therapy during SRS. The Oncologist 2016;21:244-251 Implications for Practice: Treatment of patients with brain metastases requires a multidisciplinary approach. Stereotactic radiosurgery is increasingly used in the upfront setting to treat new brain metastasis. Targeted therapies have revolutionized systemic treatment of many malignancies and may sometimes be used as initial treatment in metastatic patients. There is sparse literature regarding safety and efficacy of combining these two treatment modalities. This article summarizes the supporting literature and highlights ongoing clinical trials in combining radiosurgery with targeted therapy.

show abstract

“…In addition, detection of metastatic lesions has improved because of increased use of magnetic resonance imaging. Patients with BM often have poor prognosis and survival [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Moreover, in approximately every tenth patient, the diagnosis of brain metastasis is the first sign of the cancer disease. [1] CNS metastases are the most common intra-axial malignancies, accounting for more than 50% of all brain tumors, [2] occurring in 20-40% of patients with cancer, and leading to symptoms during lifetime in about 60-75%. [3] Autopsy series identified CNS metastases in 15-41% of patients with known primary cancers at the time of death.…”

Section: Introductionmentioning

confidence: 99%

Interdisciplinary management of central nervous system metastasis and neoplastic meningitis: recent developments and future perspectives

Tabatabai¹,

Koch²,

Roggia³

et al. 2016

JCMT

View full text Add to dashboard Cite

The incidence of metastatic disease in the central nervous system (CNS) is rising. According to current estimates, up to a third of adult cancer patients will suffer from CNS metastasis. Clinical evidence-based data from prospective randomized trials are rare, however, because CNS metastasis patients were often excluded from clinical trial participation. The management of CNS metastasis patients is therefore rather ill-defined and an interdisciplinary challenge. Recent basic and translational science data have begun contributing to a more profound understanding of the molecular mechanisms leading to invasion of tumor cells into the CNS. This report reviews advances, challenges, and perspectives in this field.

show abstract

“…Lung, breast and melanoma are the 1, 2, 3 most common cancers that metastasize to the brain [4]. The prognosis for these patients is worse than for primary CNS malignancies -3.7 vs.10-12 months for GBM [5].…”

Section: Introductionmentioning

confidence: 99%

“…Intracranial tumors, primary as well as metastatic, are increasing at an alarming rate since many patients with excellent quality of life who appear to have 'beaten the odds' develop metastatic disease to the brain after years of remission from breast and other cancers [3][4][5][6]. The development of CNS metastasis results in progressive physical and cognitive impairment and culminates in death within a few months of diagnosis.…”

Section: Introductionmentioning

confidence: 99%

A Rational for Novel Anti-NeuroOncology Drugs

Morgan¹

2013

Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications

View full text Add to dashboard Cite

Demographics of Brain Metastasis

Cited by 300 publications

References 69 publications

The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases

The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases

Interdisciplinary management of central nervous system metastasis and neoplastic meningitis: recent developments and future perspectives

A Rational for Novel Anti-NeuroOncology Drugs

Contact Info

Product

Resources

About